Surrozen
Surrozen is a clinical-stage biopharmaceutical company that engineers multivalent antibodies to selectively activate Wnt signaling for the treatment of retinal vascular diseases, with a pipeline of drug candidates for wet AMD, diabetic macular edema, and uveitic macular edema.
- Company typePublic
- Founded2016
- HeadquartersSouth San Francisco, United States
- Headcount11–50
- GTM typeB2B
- OfferingServices
What Surrozen does
Surrozen is a clinical-stage biopharmaceutical company developing antibody therapeutics that selectively activate the Wnt signaling pathway to drive tissue repair and vascular regeneration in the eye. Founded in 2016 in South San Francisco and publicly listed on Nasdaq under ticker SRZN, the company operates with 11-50 employees and is led by CEO Craig Parker. Its proprietary SWAP (Surrozen Wnt Signal Activating Proteins) platform engineers multivalent antibodies capable of combining Wnt pathway activation with modulation of other disease drivers such as VEGF and IL-6, addressing ophthalmic indications with high unmet need including wet age-related macular degeneration, diabetic macular edema, and uveitic macular edema.
The pipeline comprises SZN-413 (a FZD4-targeting bispecific Wnt agonist licensed to Boehringer Ingelheim, with a milestone achieved in 2025), SZN-8141 (a FZD4/VEGF bifunctional antibody with IND filing expected in H2 2026), SZN-8143 (a FZD4/VEGF/IL-6 trifunctional antibody with IND expected in 2027), and SZN-113 (a multi-Wnt-receptor agonist for corneal and retinal degenerative conditions). The company discontinued its SZN-043 liver disease candidate in March 2025 to focus exclusively on ophthalmology.
The business model is a hybrid of out-licensing (SZN-413 to Boehringer Ingelheim) and future direct commercialization of wholly-owned ophthalmology assets. With no commercial products today, Surrozen generates de minimis collaboration revenue (Q4 2025: $0.53M) and is funded by a $175M oversubscribed private placement completed in March 2025, alongside public equity capital. Target customers are ultimately retinal specialists and their patients, with the company signaling a traditional biotech GTM of clinical development, analyst/investor engagement, and strategic licensing partnerships rather than direct sales infrastructure.
Surrozen firmographics
Firmographics- Name
- Surrozen
- Legal name
- Surrozen, Inc.
- Website
- https://surrozen.com
- Company type
- Public
- Founded year
- 2016
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Surrozen is a clinical-stage biopharmaceutical company that engineers multivalent antibodies to selectively activate Wnt signaling for the treatment of retinal vascular diseases, with a pipeline of drug candidates for wet AMD, diabetic macular edema, and uveitic macular edema.
- Ownership category
- akta.pro rank
Surrozen industry classification
Industry- Product category
- Ophthalmic Biopharmaceutical Therapeutics
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Ophthalmology Specialty Pharmaceuticals (HLAIACAK)
Keywords
Where Surrozen is headquartered
LocationHeadquarters
- HQ city
- South San Francisco
- HQ country
- United States
- HQ region
- North America
Markets served
Surrozen business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Technology or R&D, Personnel, Operations, Others
Revenue model
- Pharmaceutical Product Revenue: Surrozen is a clinical-stage biopharmaceutical company with no current product revenue. The company is developing drug candidates targeting ophthalmic diseases and plans to commercialize pipeline assets upon regulatory approval. Future revenue will come from product sales, likely through licensing agreements or direct commercialization.
- Licensing and Collaboration Revenue: The company has licensing arrangements such as the Boehringer Ingelheim collaboration for SZN-413, which may generate milestone payments and potential royalties. The March 2025 $175M private placement discontinuing liver disease candidate SZN-043 indicates strategic focus on ophthalmology programs with potential partnership revenue.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels5 records
Surrozen product offering
Product offeringCore offering
Surrozen is a clinical-stage biopharmaceutical company that develops multifunctional antibody therapeutics targeting the Wnt signaling pathway for ophthalmic diseases. Using its proprietary SWAP platform, Surrozen engineers multivalent antibodies that selectively activate Wnt signaling in ocular tissues to treat retinal vascular diseases including wet AMD, diabetic macular edema, and uveitic macular edema. The pipeline includes SZN-413 (licensed to Boehringer Ingelheim), SZN-8141, SZN-8143, and SZN-113.
Product overview
Surrozen is a clinical-stage biotechnology company that has developed a proprietary antibody-engineering platform to discover multifunctional antibodies targeting ophthalmic diseases. The company's pipeline includes multiple drug candidates: SZN-413 (FZD4 agonist, licensed to Boehringer Ingelheim), SZN-8141 (FZD4 + VEGF bifunctional antibody for wet AMD and DME), SZN-8143 (trifunctional antibody targeting FZD4, VEGF, and IL-6), and SZN-113 (agonist for FZD1, FZD2, FZD7 receptors). The underlying technology platform, SWAP (Surrozen Wnt Signal Activating Proteins), enables multivalent antibodies that potently and selectively activate Wnt signaling for tissue repair and regeneration.
Differentiator
Problem solved
Functional benefit
Brands
- SWAPs (Surrozen Wnt Signal Activating Proteins): Proprietary multivalent antibodies that potently and selectively activate Wnt signaling in ocular tissues
Products and services
- SZN-413
Quantifiable outcome
- SZN-8141 peak probability-adjusted net sales projected at $895 million for diabetic macular edema and $614 million for neovascular age-related macular degeneration
- +2 more outcomes
Companies that use Surrozen
Customer profileSegments2 records
Ideal customer profiles2 records
Surrozen technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Surrozen partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Boehringer IngelheimcoreStrategic collaboration with Boehringer Ingelheim for SZN-413, a targeted bispecific Wnt agonist antibody for the treatment of retinal vascular diseases such as wet AMD and DME. Boehringer Ingelheim has licensed SZN-413 from Surrozen and is responsible for further development and potential commercialization. A milestone achievement by Boehringer Ingelheim for SZN-413 was reported in 2025.
Scale indicators7 records
Recent moves6 records
Expansion highlights6 records
Surrozen competitors and assessment
Company assessmentDirect peers
- Kodiak Sciences: Clinical-stage biopharmaceutical company developing novel therapeutics for retinal vascular diseases including wet AMD and DME. Directly comparable as a small-cap ophthalmology biotech pursuing next-generation alternatives to anti-VEGF therapy with a pipeline of biologic candidates.
- Adverum Biotechnologies: Clinical-stage gene therapy company focused on wet AMD and diabetic retinopathy. Directly comparable as a small-cap ophthalmology biotech developing novel mechanism therapies for retinal vascular disease.
- Ocular Therapeutix: Clinical-stage biopharmaceutical company developing therapies for retinal diseases and other ophthalmic conditions including wet AMD. Comparable as a public ophthalmology-focused biotech with multiple pipeline assets in retinal disease.
- Apellis Pharmaceuticals: Commercial-stage biopharmaceutical company with Syfovre and Empaveli for ophthalmology indications including geographic atrophy. Directly comparable as an ophthalmology-focused biotech, though more advanced commercially.
- Outlook Therapeutics: Clinical-stage biopharmaceutical company developing ONS-5010/LYTENAVA, a candidate treatment for wet AMD. Directly comparable as a small ophthalmology-focused biotech targeting the wet AMD market.
- Annexon Biosciences: Clinical-stage biopharmaceutical company developing complement-mediated therapies for ophthalmology (geographic atrophy) and neurology. Comparable as a clinical-stage biotech with novel mechanism ophthalmology programs.
Emerging players
- REGENXBIO: Clinical-stage gene therapy company with ABBV-RGX-314 for wet AMD in collaboration with AbbVie. Comparable for its ophthalmology pipeline and partnership-driven business model, though using a different modality (gene therapy).
- Lineage Cell Therapeutics: Clinical-stage cell therapy company with OPC1 for retinal indications. Comparable as a small-cap biotech developing novel regenerative therapies for ophthalmology, with a different modality (cell therapy).
Broad incumbents
- Regeneron Pharmaceuticals: Large biopharmaceutical company commercializing EYLEA (aflibercept), the market-leading anti-VEGF therapy for wet AMD and DME. Comparable as the dominant incumbent Surrozen's pipeline aims to disrupt in retinal disease.
- Genentech (Roche): Major biopharmaceutical company marketing Lucentis and Vabysmo for wet AMD and DME. Comparable as an entrenched anti-VEGF incumbent whose products define the current standard of care Surrozen's candidates aim to improve upon.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks5 records
Key highlights6 records
Customer concentration
Surrozen social profiles
Digital presenceSurrozen financial estimates
Financial estimateRevenue estimate
Valuation estimate
Surrozen leadership team
Management profileNumber of profiles
Profiles7 records
Surrozen funding detail
Funding detailFunding overview
Funding rounds6 records
Investors19 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Surrozen M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Surrozen
What does Surrozen do?
Surrozen is a clinical-stage biopharmaceutical company that develops multifunctional antibody therapeutics targeting the Wnt signaling pathway for ophthalmic diseases. Using its proprietary SWAP platform, Surrozen engineers multivalent antibodies that selectively activate Wnt signaling in ocular tissues to treat retinal vascular diseases including wet AMD, diabetic macular edema, and uveitic macular edema. The pipeline includes SZN-413 (licensed to Boehringer Ingelheim), SZN-8141, SZN-8143, and SZN-113.
Is Surrozen a public or private company?
Surrozen is a public company. It is classified as public and is currently operating.
When was Surrozen founded?
Surrozen was founded in 2016. It employs 11 to 50 people.
Where is Surrozen based?
Surrozen is headquartered in South San Francisco, United States, in the North America region.
How does Surrozen make money?
Two revenue lines are on record. Pharmaceutical Product Revenue is the primary driver. The others are licensing and Collaboration Revenue.
Who are Surrozen's main competitors?
Direct peers on record are Kodiak Sciences, Adverum Biotechnologies, Ocular Therapeutix, Apellis Pharmaceuticals, Outlook Therapeutics and Annexon Biosciences. Emerging players are REGENXBIO and Lineage Cell Therapeutics. Broad incumbents are Regeneron Pharmaceuticals and Genentech (Roche).
Does Surrozen have an API?
No public API is recorded for Surrozen.
What industry is Surrozen in?
Surrozen's product category is Ophthalmic Biopharmaceutical Therapeutics. Its primary akta.pro industry code is HLAIACAK, Ophthalmology Specialty Pharmaceuticals. Its NAICS code is 325414 and its SIC code is 2834.